Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ipilimumab · 1 trial · 1 indication
Number of participants with complete response or partial response within the first 6 months or stable disease lasting for minimum 6 months
| Arm | Type | Description |
|---|---|---|
| Anti-CTLA-4, SBRT and PD1 | EXPERIMENTAL | Participants will receive 1 dose of ipilimumab (1mg/kg intravenously) on day 1. After 1 week the participants will receive SBRT (3x8Gy) on at least 1 but no more than 4 tumor lesions. Within 1 week of the last radiation fraction participants will start with cemiplimab (350mg intravenously every 3 weeks) until disease progression, unacceptable toxicity, patient request for discontinuation, or up to 2 years of treatment |
| Name | Type | Description |
|---|---|---|
| Ipilimumab | DRUG | Anti-CTLA-4 |
| Cemiplimab | DRUG | PD-1 inhibition |
| SBRT | RADIATION | Stereotactic Body Radiotherapy |
Inclusion Criteria: 1. Have proven diagnosis of recurrent advanced NSCLC, irrespective of histological subtype. 2. Be willing and able to provide written informed consent/assent for the trial. 3. Must still have measurable disease based on RECIST 1.1 after application of study SBRT. Lesions that we...
Ipilimumab is being studied for the treatment of carcinoma, non-small-cell lung. It is currently in Phase 2 clinical development as an investigational therapy for this condition.
Ipilimumab is a monoclonal antibody, classified as a -mab antibody. It is being evaluated for its role in immune modulation in the context of non-small-cell lung cancer.
Ipilimumab is being developed by Sanofi, a biopharmaceutical company listed on the stock exchange under the ticker symbol SNY.
Ipilimumab is currently in Phase 2 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities for any indication.
Ipilimumab is being studied in a Phase 2 clinical trial with the identifier NCT05401786. This trial is titled 'Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC' and is active but not recruiting participants.
Ipilimumab is a distinct drug entity. It is a monoclonal antibody being investigated for its potential role in treating non-small-cell lung cancer, and no alternative names have been associated with it in the context of this development program.